Screener
Bicara Therapeutics BCAX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 29,948 | 18,898 |
| Accrued expenses and other current liabilities – related party | 812 | 1,141 |
| Operating lease liability – current portion | 1,140 | 1,117 |
| Total current liabilities | 39,340 | 28,949 |
| Operating lease liability – net of current portion | 301 | 593 |
| Total liabilities | 39,641 | 29,542 |
| Commitments and Contingencies (Note 7) | ||
| Stockholders' equity: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's total current liabilities?
- Bicara Therapeutics (BCAX) reported total current liabilities of $39.34M in Q1 2026.
- How has Bicara Therapeutics's total current liabilities changed year-over-year?
- Bicara Therapeutics's total current liabilities increased by 105.8% year-over-year, from $19.12M to $39.34M.
- What is the long-term trend for Bicara Therapeutics's total current liabilities?
- Over 2 years (2023 to 2025), Bicara Therapeutics's total current liabilities has grown at a 38.5% compound annual growth rate (CAGR), from $15.09M to $28.95M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Bicara Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude